Table 5. The adjusted associations of biomarkers, ‘classic’ scores and ‘composed’ scores with unfavourable 30-day functional outcome of ischemic stroke, with model discriminatory ability and goodness of model fit, and pairwise comparison of each model.

		Adjusted analysis		Model discriminatory ability		Model fit	Pairwise comparisons of the ROC curves
	Variable	OR (95% CI)	P	c-statistic (95% CI)	P	Hosmer-Lemeshow test (HL)	z-statistic	P	IDI
						Nagelkerke R square (NR2)			P
									0.00801
1	TnI (quartiles)	1.8 (1.1–3.2)	0.036	0.957 (0.931–0.983)	<0.001	HL 0.036; NR2 0.786	2.576 (3 vs. 1)	0.0100	(3 vs. 4)
2	Fibrinogen (quartiles)	2.2 (1.8–4.1)	0.013	0.957 (0.931–0.983)	<0.001	HL 0.036; NR2 0.786	2.576 (3 vs. 2)	0.0100	P = 0.15460
3	CHA2DS2-VASc	14.1 (3.4–59.5)	<0.001	0.982 (0.964–1.000)	<0.001	HL <0.001; NR2 0.870	0.369 (4,5 vs. 3)	0.7119	0.00172
4	CHA2DS2-VASc-T	22.5 (3.1–162.9)	0.002	0.983 (0.963–1.000)	<0.001	HL <0.001; NR2 0.877	2.588 (4 vs. 1,2)	0.0097	(3 vs. 5)
5	CHA2DS2-VASc-CRPFT	7.7 (1.8–32.7)	0.006	0.983 (0.963–1.000)	<0.001	HL <0.001; NR2 0.877	2.588 (5 vs. 1,2)	0.0097	P = 0.61428

OR, Odds Ratio; CI, Confidence Interval; ROC, Receiver Operating Characteristic; IDI – integrated discrimination index.

Only biomarkers or scores with significant association with unfavourable 30-day functional stroke outcome following adjustment are shown.

Cardiac TnI and fibrinogen adjusted for other biomarkers (white blood cell count, haemoglobin, haematocrit, C-reactive protein, D-dimer, creatinine clearance, total cholesterol, high-density lipoprotein and low-density lipoprotein), age, gender, body mass index, smoking status, alcohol consumption, NYHA class, atrial fibrillation, history of hypertension, heart failure, diabetes mellitus, chronic kidney disease, prior stroke/TIA, left atrial volume, left ventricular ejection fraction, the presence of mitral annular calcification and symptomatic haemorrhagic transformation of ischemic stroke.

The CHA₂DS₂-VASc score adjusted for CHADS₂ and HAS-BLED score, all biomarkers, gender, body mass index, smoking status, alcohol consumption, NYHA class, atrial fibrillation, chronic kidney disease, left atrial volume, left ventricular ejection fraction, the presence of mitral annular calcification and symptomatic haemorrhagic transformation of ischemic stroke.

The CHA₂DS₂-VASc-T and CHA₂DS₂-VASc-CRPFT scores adjusted for all blood biomarkers, gender, body mass index, smoking status, alcohol consumption, NYHA class, atrial fibrillation, chronic kidney disease, left atrial volume, left ventricular ejection fraction, the presence of mitral annulus calcification and symptomatic haemorrhagic transformation of ischemic stroke.